References
- Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148–152.
- Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003;102:2960–2968.
- Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med 1999; 19:157–167.
- Muramatsu H, Kato K, Watanabe N, et al. Risk factors for early death in neonates with Down syndrome and transient leukemia. Br J Haematol 2008;142:610–615.
- Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006;107:4606–4613.
- Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991–2998.
- Shimada A, Hayashi Y, Ogasawara M, et al. Pro-inflammatory cytokinemia is frequently found in Down syndrome patients with hematological disorders. Leuk Res 2007;31:1199–1203.
- Hattori H, Matsuzaki A, Suminoe A, Ihara K, Nakamura H, Hara T. High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and fibrosis. Br J Haematol 2001;115:472–475.
- Al Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002;24:9–13.
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of oesophagus for bleeding oesophageal verices. Br J Surg 1973;60:646–649.
- Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation–on behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001;86:1327–1330.
- McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000;15: 945–951.
- Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558–563.
- Shiozawa Y, Fujita H, Fujimura J, et al. A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers. Pediatr Hamatol Oncol 2004;21:273–278.
- Kuroiwa Y, Suzuki N, Yamamoto M, Hatakeyama N, Hori T, MIzue N. Prognostic value of serum markers for liver fibrosis in transient abnormal myelopoiesis (TAM). Jpn J Clin Hematol 2005;46:1179–1186.